68Ga-R11228

**68Ga-R11228** is a gallium-68-labeled small molecule radioligand developed by Radionetics Oncology for **diagnostic imaging in breast cancer**[1][2][3][4]. It is administered intravenously to visualize cancer lesions, particularly in metastatic or locoregionally recurrent estrogen or progesterone receptor-positive, HER2-negative breast cancer, using positron emission tomography (PET). The radioligand targets tumor tissue, allowing precise detection and quantification of lesions for diagnostic purposes. As a radiopharmaceutical, its mechanism centers on binding to molecular targets that can be imaged via PET, rather than direct modulation of tumor biology[1][2][3][4].